EG 427

Bladder
#EG 427 #Financing #Genetic medicines #Neurodegenerative disorders

EG 427 raises €27m to finance genetic medicines in neuro-urology

EG 427 has announced the successful closing of a €27 million Series B financing round co-led by Andera Partners and Bpifrance – as part of the InnoBio investment strategy.    The proceeds from the financing will be used to fund the Phase Ib/IIa development of EG 427’s lead genetic medicine product,… Read More

#Business & Investment #News

#EG 427 #Gene therapy #Neurology #Phase II trial

First gene therapy for bladder condition enters clinical study

Biotechnology company EG 427 has revealed plans to start a Phase Ib/IIa clinical study in neurogenic detrusor overactivity (NDO), following Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA). NDO is a severe bladder condition affecting patients living with spinal cord injury,… Read More

#News